Science and Research

A Phase 3 Multicenter, Randomized, Open Label, active-controlled, Study of AMG 510 Versus Docetaxel for the Treatment of previously treated Locally Advanced and unresectable or Metastatic NSCLC Subjects with KRAS p.G12C Mutation

A Phase 3 Study to Compare AMG 510 with Docetaxel in Non Small Cell Lung Cancer (NSCLC) subjects with KRAS p. G12c mutation

Study details
Study-ID: NCT04303780, 2019-003582-18
Study-ID: NCT04303780, 2019-003582-18
DZL Disease Area: LC
DZL Disease Area: LC
Study Type: Interventional
Study Type: Interventional
DZL Role: DZL on steering board
DZL Role: DZL on steering board
Funding: Externally - industry
Funding: Externally - industry
DZL Participating Sites: ARCN
DZL Participating Sites: ARCN
Start Date: 04.06.2020
Completion Date: 25.02.2026
Status: Active / not recruiting
Status: Active / not recruiting
DZL on steering board
Link to Study


close
chevron-down

Unsere Seite verwendet Cookies und ähnliche Technologien. Mit der Nutzung der Webseite stimmen Sie der Verwendung von Cookies zu. Mehr Informationen dazu finden Sie in unserer Datenschutzerklärung.